Cargando…

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo

FDA-approved anti-PD-L1 antibody drug Atezolizumab is a human IgG1 without glycosylation by an N297A mutation. Aglycosylation of IgG1 has been used to completely remove the unwanted Fc-mediated functions such as antibody-dependent cytotoxicity (ADCC). However, aglycosylated Atezolizumab is unstable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Maohua, Zhao, Rongqing, Chen, Jianxin, Tian, Wenzhi, Xia, Chenxi, Liu, Xudong, Li, Yingzi, Li, Song, Sun, Hunter, Shen, Tong, Ren, Wenlin, Sun, Le
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952408/ https://www.ncbi.nlm.nih.gov/pubmed/33707569 http://dx.doi.org/10.1038/s41598-021-85329-9

Ejemplares similares

Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Li, Maohua, et al.
Publicado: (2022)

Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy
por: Zhao, Rongqing, et al.
Publicado: (2020)

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
por: Zhang, Fei, et al.
Publicado: (2017)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Pneumonia Caused by Coinfection with Cytomegalovirus and Pneumocystis jirovecii in an HIV-Negative Infant Diagnosed by Metagenomic Next-Generation Sequencing
por: Lyu, Jingwen, et al.
Publicado: (2022)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
por: Mabbitt, Joseph, et al.
Publicado: (2023)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
por: Kowanetz, Marcin, et al.
Publicado: (2018)

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
por: Gomez-Roca, Carlos, et al.
Publicado: (2022)

Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates
por: Ren, Wenlin, et al.
Publicado: (2020)

Atezolizumab alleviates the immunosuppression induced by PD-L1-positive neutrophils and improves the survival of mice during sepsis
por: Chen, Jianxin, et al.
Publicado: (2021)

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
por: Parisi, Alessandro, et al.
Publicado: (2019)

The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action, and In Vivo and Ex Vivo Efficacy
por: Krishna, Neel K., et al.
Publicado: (2022)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
por: Powles, Thomas, et al.
Publicado: (2015)

In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody
por: Rattanapisit, Kaewta, et al.
Publicado: (2023)

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
por: Lin, Shen, et al.
Publicado: (2022)

Next-generation GRAB sensors for monitoring dopaminergic activity in vivo
por: Sun, Fangmiao, et al.
Publicado: (2020)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
por: Patil, Namrata S., et al.
Publicado: (2021)

The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice
por: Li, Panyuan, et al.
Publicado: (2020)

Diagnostic performance and clinical impact of blood metagenomic next-generation sequencing in ICU patients suspected monomicrobial and polymicrobial bloodstream infections
por: Liu, Qilong, et al.
Publicado: (2023)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma
por: Giovannini, Catia, et al.
Publicado: (2023)

Engineered systems of inducible anti-repressors for the next generation of biological programming
por: Groseclose, Thomas M., et al.
Publicado: (2020)

Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics
por: Porsbjerg, Celeste M., et al.
Publicado: (2020)

Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy
por: Wei, Jing, et al.
Publicado: (2023)

The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer
por: Zheng, Wubin, et al.
Publicado: (2022)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Diagnosis of Mycobacterium tuberculosis Septic Shock in Patients With Anti-synthetase Syndrome Based on Next-Generation Sequencing: A Case Report and Literature Review
por: Sun, Limin, et al.
Publicado: (2021)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023)

Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model
por: Li, Pan, et al.
Publicado: (2022)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu, Nagashree, et al.
Publicado: (2017)

Atezolizumab, a PD-L1 Inhibitor: An Association of Bleeding Gastric Ulcer With Its Use
por: Bapatla, Anusha, et al.
Publicado: (2021)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics
por: Cox, Robert, et al.
Publicado: (2015)

Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
por: Du, Fanny Huynh, et al.
Publicado: (2017)

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
por: Minchom, Anna, et al.
Publicado: (2018)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody
por: Furuya, Naoki, et al.
Publicado: (2021)

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
por: Topp, Max S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bfqts8lehcfo1fndf2n1p6uk05